MA32938B1 - Composes organiques - Google Patents

Composes organiques

Info

Publication number
MA32938B1
MA32938B1 MA33969A MA33969A MA32938B1 MA 32938 B1 MA32938 B1 MA 32938B1 MA 33969 A MA33969 A MA 33969A MA 33969 A MA33969 A MA 33969A MA 32938 B1 MA32938 B1 MA 32938B1
Authority
MA
Morocco
Prior art keywords
organic compounds
compounds
organic
subject
Prior art date
Application number
MA33969A
Other languages
Arabic (ar)
English (en)
Inventor
Jun Zhao
Hailin Zeng
Peng Li
Lawrence P Wennogle
Original Assignee
Intra Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42233533&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32938(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intra Cellular Therapies Inc filed Critical Intra Cellular Therapies Inc
Publication of MA32938B1 publication Critical patent/MA32938B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

3-(THIO, SULFINYL OU SULFONYL)-7,8-DIHYDRO-(1H OU 2H)-IMIDAZO[1,2-A]PYRAZOLO[4,3-E]PYRIMIDIN-4(5H)-ONES ÉVENTUELLEMENT SUBSTITUÉES, 3-(THIO, SULFINYL OU SULFONYL)-7,8,9-TRIHYDRO'(1H OU 2H)-PYRIMIDO[1,2-A]PYRAZOLO[4,3-E]PYRIMIDIN-4(5?)-ONES OU COMPOSÉS DE FORMULE (I), LEURS PROCÉDÉS DE PRODUCTION, LEUR EMPLOI EN TANT QUE PRODUITS PHARMACEUTIQUES ET LES COMPOSITIONS PHARMACEUTIQUES LES INCLUANT.
MA33969A 2008-12-06 2009-12-07 Composes organiques MA32938B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12044208P 2008-12-06 2008-12-06
PCT/US2009/006439 WO2010065149A1 (fr) 2008-12-06 2009-12-07 Composés organiques

Publications (1)

Publication Number Publication Date
MA32938B1 true MA32938B1 (fr) 2012-01-02

Family

ID=42233533

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33969A MA32938B1 (fr) 2008-12-06 2009-12-07 Composes organiques

Country Status (23)

Country Link
US (4) US8536159B2 (fr)
EP (1) EP2367429B1 (fr)
JP (1) JP5778582B2 (fr)
KR (1) KR20110095881A (fr)
CN (1) CN102231953A (fr)
AU (1) AU2009322901A1 (fr)
BR (1) BRPI0922348A2 (fr)
CA (1) CA2740391A1 (fr)
CL (1) CL2011001263A1 (fr)
CO (1) CO6390083A2 (fr)
CR (1) CR20110312A (fr)
DO (1) DOP2011000173A (fr)
EA (1) EA201170770A1 (fr)
EC (1) ECSP11011184A (fr)
ES (1) ES2638912T3 (fr)
IL (1) IL213314A0 (fr)
MA (1) MA32938B1 (fr)
MX (1) MX2011005933A (fr)
PE (1) PE20110922A1 (fr)
SG (1) SG171775A1 (fr)
TN (1) TN2011000246A1 (fr)
WO (1) WO2010065149A1 (fr)
ZA (1) ZA201103631B (fr)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5084725B2 (ja) 2005-06-06 2012-11-28 武田薬品工業株式会社 有機化合物
WO2007143705A2 (fr) 2006-06-06 2007-12-13 Intra-Cellular Therapies, Inc. Composés organiques
EP2081431B1 (fr) * 2006-11-13 2013-01-16 Intra-Cellular Therapies, Inc. Composés organiques
JP5837278B2 (ja) 2006-12-05 2015-12-24 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規使用
CN104370918A (zh) 2007-12-06 2015-02-25 武田药品工业株式会社 有机化合物
JP5701608B2 (ja) * 2007-12-06 2015-04-15 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
BRPI0922131A2 (pt) * 2008-12-06 2015-08-18 Intracellular Therapies Inc Compostos orgânicos
EP2367430B1 (fr) 2008-12-06 2014-08-13 Intra-Cellular Therapies, Inc. Composés organiques
EA201170773A1 (ru) 2008-12-06 2012-01-30 Интра-Селлулар Терапиз, Инк. Органические соединения
BRPI0922808A2 (pt) 2008-12-06 2018-05-29 Intracellular Therapies Inc compostos orgânicos
MX2011005933A (es) * 2008-12-06 2011-12-16 Intra Cellular Therapies Inc Compuestos organicos.
BRPI0922809A2 (pt) 2008-12-06 2018-05-29 Intracellular Therapies Inc compostos orgânicos
US11464781B2 (en) 2009-02-25 2022-10-11 Intra-Cellular Therapies, Inc. PDE1 inhibitors for ophthalmic disorders
JP2012526810A (ja) 2009-05-13 2012-11-01 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
JP2013507360A (ja) * 2009-10-08 2013-03-04 イントラ−セルラー・セラピーズ・インコーポレイテッド ホスホジエステラーゼ１−標的トレーサーおよび方法
EP2590657A4 (fr) 2010-05-31 2014-02-12 Intra Cellular Therapies Inc Composés organiques
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
US9434730B2 (en) 2010-05-31 2016-09-06 Intra-Cellular Therapies, Inc. PDE1 inhibitor compounds
WO2011153138A1 (fr) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Composés organiques
WO2012171016A1 (fr) * 2011-06-10 2012-12-13 Intra-Cellular Therapies, Inc. Composés organiques
ES2885523T3 (es) 2011-11-23 2021-12-14 Therapeuticsmd Inc Formulaciones y terapias de reposición hormonal de combinación naturales
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
AU2013277294C1 (en) 2012-06-18 2018-02-08 Dart Neuroscience (Cayman) Ltd Substituted thiophene- and furan-fused azolopyrimidine-5-(6h)-one compounds
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
AR091507A1 (es) 2012-06-21 2015-02-11 Intra Cellular Therapies Inc SALES DE (6aR,9aS)-5,6a,7,8,9,9a-HEXAHIDRO-5-METIL-3-(FENILAMINO)-2-((4-(6-FLUOROPIRIDIN-2-IL)FENIL)METIL)-CICLOPENT[4,5]IMIDAZO[1,2-a]PIRAZOLO[4,3-e]PIRIMIDIN-4(2H)-ONA
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
EP2956141A4 (fr) 2013-02-17 2016-10-26 Intra Cellular Therapies Inc Nouvelles utilisations
PL2970279T3 (pl) 2013-03-15 2021-05-31 Intra-Cellular Therapies, Inc. Związki organiczne
EP2968338B1 (fr) * 2013-03-15 2019-01-09 Intra-Cellular Therapies, Inc. Inhibiteurs de pde1 utilisés dans le traitement et/ou la prévention de blessures du snc et de maladies, de troubles ou de blessures du snp
ES2894770T3 (es) 2013-06-21 2022-02-15 Intra Cellular Therapies Inc Cristales de base libre
US9849132B2 (en) 2014-01-08 2017-12-26 Intra-Cellular Therapies, Inc. Products and pharmaceutical compositions
MX2016014281A (es) 2014-05-22 2017-02-22 Therapeuticsmd Inc Formulaciones y terapias de reemplazo de combinación de hormonas naturales.
DK3157926T3 (da) 2014-06-20 2019-08-19 Intra Cellular Therapies Inc Organiske forbindelser
MX2016013693A (es) 2014-07-29 2017-10-31 Therapeuticsmd Inc Crema transdermica.
US10285992B2 (en) 2014-08-07 2019-05-14 Intra-Cellular Therapies, Inc. Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
US9546175B2 (en) 2014-08-07 2017-01-17 Intra-Cellular Therapies, Inc. Organic compounds
US10131671B2 (en) 2014-08-07 2018-11-20 Intra-Cellular Therapies, Inc. Organic compounds
RU2711442C2 (ru) 2014-09-17 2020-01-17 Интра-Селлулар Терапиз, Инк. Соединения и способы
MX371158B (es) 2014-12-06 2020-01-20 Intra Cellular Therapies Inc Compuestos inhibidores de pde2.
US10105349B2 (en) 2014-12-06 2018-10-23 Intra-Cellular Therapies, Inc. Organic compounds
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10682354B2 (en) 2016-03-28 2020-06-16 Intra-Cellular Therapies, Inc. Compositions and methods
AU2017239645A1 (en) 2016-04-01 2018-10-18 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
EP3509589B1 (fr) 2016-09-12 2021-11-17 Intra-Cellular Therapies, Inc. Nouvelles utilisations
US11839614B2 (en) 2018-01-31 2023-12-12 Intra-Cellular Therapies, Inc. Methods for treating or mitigating cardiotoxicity characterized by inhibition of adenosine A2 signaling and/or adenosine A2 receptor expression
EP3802545A4 (fr) 2018-05-25 2022-03-16 Intra-Cellular Therapies, Inc. Composés organiques
US20210338679A1 (en) 2018-09-25 2021-11-04 Intra-Cellular Therapies, Inc. Novel uses
US11628171B2 (en) 2019-03-13 2023-04-18 Children's Medical Center Corporation Method for treating brain or nerve injury
WO2020210614A1 (fr) 2019-04-12 2020-10-15 Intra-Cellular Therapies, Inc. Composés organiques
JP7612672B2 (ja) * 2019-09-03 2025-01-14 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規化合物
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
WO2021226407A1 (fr) 2020-05-06 2021-11-11 Intra-Cellular Therapies, Inc. Cristaux à base libre
US12364695B2 (en) 2020-06-02 2025-07-22 Intra-Cellular Therapies, Inc. Methods of treating inflammatory disease

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666908A (en) 1985-04-05 1987-05-19 Warner-Lambert Company 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use
IL98559A0 (en) 1990-06-21 1992-07-15 Schering Corp Polycyclic guanine derivatives
US5202328A (en) 1991-03-06 1993-04-13 Merck & Co., Inc. Substituted fused pyrimidinones
US5294612A (en) 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
NZ262797A (en) 1993-02-26 1997-08-22 Schering Corp Polycyclic guanine derivatives, purine and pyrimidine precursors; medicaments
GB9315017D0 (en) 1993-07-20 1993-09-01 Glaxo Lab Sa Chemical compounds
US5824683A (en) 1995-11-28 1998-10-20 Schering Corporation 2'- 4'-halo- 1,1'-biphenyl!-4-yl!methyl!-5'-methyl-spiro cyclopentane-1,7' (8'H)- 3H! imidazo 2,1-b!purin!-4' (5'H)-ones
SE9701398D0 (sv) 1997-04-15 1997-04-15 Astra Pharma Prod Novel compounds
IT1291372B1 (it) 1997-05-21 1999-01-07 Schering Plough S P A Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
US6013621A (en) 1997-10-17 2000-01-11 The Rockfeller University Method of treating psychosis and/or hyperactivity
GB9722520D0 (en) 1997-10-24 1997-12-24 Pfizer Ltd Compounds
US6133273A (en) 1998-05-08 2000-10-17 American Home Products Corporation Pyrazolopyrimidine-2,4-dione sulfonamides
DE19931206A1 (de) 1999-07-07 2001-01-11 Stief Christian Arzneimittel zur Erhöhung des cAMP-Spiegels und deren Verwendung
JP2003510325A (ja) 1999-09-30 2003-03-18 ニューロジェン・コーポレーション ある種のアルキレンジアミン−置換ピラゾロ［１，５−ａ］−１，５−ピリミジン及びピラゾロ［１，５−ａ］−１，３，５−トリアジン
KR20020038941A (ko) 1999-10-11 2002-05-24 디. 제이. 우드, 스피겔 알렌 제이 포스포디에스테라아제 억제제로서의5-(2-치환된-5-헤테로사이클릴설포닐피리드-3-일)-디하이드로피라졸로[4,3-ｄ]피리미딘-7-온
TWI265925B (en) 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
IL139073A0 (en) 1999-10-21 2001-11-25 Pfizer Treatment of neuropathy
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
AU2001255849B8 (en) 2000-04-19 2006-04-27 Lilly Icos, Llc. PDE-V inhibitors for treatment of Parkinson's Disease
WO2002074312A1 (fr) 2001-03-16 2002-09-26 Pfizer Limited Composes pyrazolo[4,3-d]pyrimidinone en tant qu'inhibiteurs de gmpc pde
WO2002088079A2 (fr) * 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Inhibiteurs doubles de pde 7 et pde 4
SE0102315D0 (sv) 2001-06-28 2001-06-28 Astrazeneca Ab Compounds
ATE395349T1 (de) 2001-08-28 2008-05-15 Schering Corp Polycyclische guanin phosphodiesterase inhibitoren
US20030211040A1 (en) 2001-08-31 2003-11-13 Paul Greengard Phosphodiesterase activity and regulation of phosphodiesterase 1B-mediated signaling in brain
CA2465893A1 (fr) * 2001-11-09 2003-05-22 Schering Corporation Inhibiteurs de la phosphodiesterase v de derives polycycliques de guanine
EP1476200A4 (fr) 2002-02-21 2008-08-13 Univ Rockefeller Compositions et methodes de regulation de la signalisation dependant du calcium dans le cerveau
GB0230045D0 (en) 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
WO2004087906A1 (fr) 2003-03-31 2004-10-14 Pfizer Products Inc. Structure cristalline de 3',5'-phosphodiesterase nucleotidique cyclique 1d(pde1b) et ses utilisations
US7153824B2 (en) 2003-04-01 2006-12-26 Applied Research Systems Ars Holding N.V. Inhibitors of phosphodiesterases in infertility
AP2006003559A0 (en) 2003-09-05 2006-04-30 Neurogen Corp Ventis Pharmaceuticals Inc Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF 1 receptor ligands
JP5084725B2 (ja) 2005-06-06 2012-11-28 武田薬品工業株式会社 有機化合物
US20080194592A1 (en) 2005-08-23 2008-08-14 Intra-Cellular Therapies, Inc. Organic Compounds
WO2007143705A2 (fr) 2006-06-06 2007-12-13 Intra-Cellular Therapies, Inc. Composés organiques
US20070286890A1 (en) * 2006-06-07 2007-12-13 John Garnett Walt Eyelash applicator and method
EP2081431B1 (fr) 2006-11-13 2013-01-16 Intra-Cellular Therapies, Inc. Composés organiques
JP5837278B2 (ja) 2006-12-05 2015-12-24 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規使用
CN104370918A (zh) 2007-12-06 2015-02-25 武田药品工业株式会社 有机化合物
JP5701608B2 (ja) 2007-12-06 2015-04-15 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
EP2367430B1 (fr) 2008-12-06 2014-08-13 Intra-Cellular Therapies, Inc. Composés organiques
BRPI0922808A2 (pt) 2008-12-06 2018-05-29 Intracellular Therapies Inc compostos orgânicos
MX2011005933A (es) * 2008-12-06 2011-12-16 Intra Cellular Therapies Inc Compuestos organicos.
BRPI0922131A2 (pt) 2008-12-06 2015-08-18 Intracellular Therapies Inc Compostos orgânicos
BRPI0922809A2 (pt) 2008-12-06 2018-05-29 Intracellular Therapies Inc compostos orgânicos
EA201170773A1 (ru) 2008-12-06 2012-01-30 Интра-Селлулар Терапиз, Инк. Органические соединения
US11464781B2 (en) 2009-02-25 2022-10-11 Intra-Cellular Therapies, Inc. PDE1 inhibitors for ophthalmic disorders
JP2012526810A (ja) 2009-05-13 2012-11-01 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
JP2013507360A (ja) 2009-10-08 2013-03-04 イントラ−セルラー・セラピーズ・インコーポレイテッド ホスホジエステラーゼ１−標的トレーサーおよび方法
EP2590657A4 (fr) 2010-05-31 2014-02-12 Intra Cellular Therapies Inc Composés organiques
WO2011153138A1 (fr) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Composés organiques
US9434730B2 (en) 2010-05-31 2016-09-06 Intra-Cellular Therapies, Inc. PDE1 inhibitor compounds
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
WO2012171016A1 (fr) * 2011-06-10 2012-12-13 Intra-Cellular Therapies, Inc. Composés organiques

Also Published As

Publication number Publication date
ECSP11011184A (es) 2011-10-31
US20110245214A1 (en) 2011-10-06
TN2011000246A1 (en) 2012-12-17
EP2367429B1 (fr) 2017-06-07
CO6390083A2 (es) 2012-02-29
ZA201103631B (en) 2013-05-29
AU2009322901A1 (en) 2010-06-10
EA201170770A1 (ru) 2012-02-28
US20160083390A1 (en) 2016-03-24
CL2011001263A1 (es) 2011-11-18
CA2740391A1 (fr) 2010-06-10
DOP2011000173A (es) 2011-10-31
CN102231953A (zh) 2011-11-02
EP2367429A4 (fr) 2012-06-06
SG171775A1 (en) 2011-07-28
KR20110095881A (ko) 2011-08-25
EP2367429A1 (fr) 2011-09-28
IL213314A0 (en) 2011-07-31
MX2011005933A (es) 2011-12-16
WO2010065149A1 (fr) 2010-06-10
JP5778582B2 (ja) 2015-09-16
US8536159B2 (en) 2013-09-17
BRPI0922348A2 (pt) 2015-08-11
JP2012510993A (ja) 2012-05-17
US20140005155A1 (en) 2014-01-02
US20150038474A1 (en) 2015-02-05
CR20110312A (es) 2011-10-28
PE20110922A1 (es) 2012-01-22
ES2638912T3 (es) 2017-10-24

Similar Documents

Publication Publication Date Title
MA32938B1 (fr) Composes organiques
MA32939B1 (fr) Composes organiques
MA32937B1 (fr) Composes organiques
CR20130045A (es) Compuestos terapéuticos
MA32877B1 (fr) Composes organiques
CR20120295A (es) Triazolopiridinas
BRPI0922351A2 (pt) compostos orgânicos
BRPI0922700A2 (pt) Compostos orgânicos
BRPI0922808A2 (pt) compostos orgânicos
BRPI0914698A2 (pt) compostos orgânicos
BRPI0909417A2 (pt) compostos orgânicos
BRPI0915018A2 (pt) compostos orgânicos
DK2310359T3 (da) Organiske forbindelser
BRPI0917574A2 (pt) compostos orgânicos
CR20120297A (es) Espironucleósidos uracílicos oxetánicos
BRPI0921826A2 (pt) compostos orgânicos
DK2288375T3 (da) Pegylerede insulin-lispro-forbindelser
BRPI0920707A2 (pt) compostos
DK2242759T3 (da) Forbindelser
BRPI0914775A2 (pt) compostos de fenila dissubstituídos
SMT201600045B (it) Composti tetraciclinici c7-fluoro sostituiti
CR20120637A (es) Triazolopiridinas sustituidas
DK2297162T3 (da) Forbindelser
UY31688A1 (es) Plaguicidas
BRPI0916432A2 (pt) compostos